Multiple Myeloma

Ashley Rosko, MD, assistant professor in the Division of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses treatment for elderly patients with multiple myeloma.

Jayesh Mehta, MD, professor of medicine (Hematology and Oncology), Feinberg School of Medicine, Northwestern University, discusses combining agents in multiple myeloma.

Higher-dose, once-weekly carfilzomib (Kyprolis) demonstrated superior efficacy for patients with relapsed/refractory multiple myeloma compared with a lower-dose, twice-weekly regimen.

Maintenance therapy with lenalidomide following autologous stem-cell transplantation conferred a survival benefit for patients with newly diagnosed multiple myeloma.

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses properly managing patients with multiple myeloma.

Induction therapy with bortezomib, cyclophosphamide, and dexamethasone induced strong response rates in treatment-naïve patients with multiple myeloma.

Ashley Rosko, MD, discusses available therapies, others under investigation, and supportive care methods being utilized for patients with multiple myeloma.

Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses combinations in multiple myeloma.

Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses treatment considerations in relapsed and refractory multiple myeloma.

The treatment approach for patients with relapsed/refractory multiple myeloma should be tailored based on biology of the disease, frailty of the patient, and comorbidities.

Shaji K. Kumar, MD, discusses proper diagnosis, risk stratification, and personalized medicine for patients with newly-diagnosed multiple myeloma.

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses the management of newly diagnosed patients with multiple myeloma.

Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the treatment of patients with newly diagnosed multiple myeloma.

The Japanese Ministry of Health, Labor and Welfare has approved the use of daratumumab (Darzalex) for the treatment of adults with relapsed/refractory multiple myeloma.

The advent of new agents and new classes of agents for treating relapsed or refractory multiple myeloma, a notably complex disease state, has stimulated efforts to identify the optimal way to sequence or combine these therapies.

The FDA has placed clinical holds on multiple trials in Celgene’s FUSION program, which is exploring regimens combining the PD-L1 inhibitor durvalumab with immunomodulatory and chemotherapy agents across several hematologic malignancies.

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the potential of checkpoint inhibitors as monotherapy and in combination.

The FDA has placed partial clinical holds on 3 trials assessing nivolumab (Opdivo)-based combinations in patients with relapsed/refractory multiple myeloma.

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses a study of ixazomib (Ninlaro) as maintenance therapy in multiple myeloma.

Peter Voorhees, MD, hematology, medical oncology, Carolinas HealthCare System, discusses optimal management of treatment-related adverse events (TRAEs) for patients with multiple myeloma.

During the past decade, the treatment of multiple myeloma has significantly changed, enabling more patients to achieve deep and durable responses.

The FDA released a statement today providing specific data from 2 phase III trials of pembrolizumab in multiple myeloma that the agency placed clinical holds on in July.

The FDA has accepted a supplemental new drug application seeking to add overall survival data from the phase III ENDEAVOR trial to the label for carfilzomib for use in patients with relapsed or refractory multiple myeloma.